CAS: 4533-39-5; Nitracrine

该化合物是一种特殊二胺衍生物,具有丙烯基硝基酯组,该化合物因其结构多功能性而引人注目,将二甲基二亚胺脊柱与硝基-丙烯基胺基体结合,可产生独特的电子和约束性特性,其潜在用途包括用作有机合成的中间体,特别是用于发展荧光探测器或DNA隔热剂,因为丙烯基酯组具有核酸的亲近性.硝基氨基氨基苯进一步增强再活性,使之适合选择性修改.该化合物的界定完善结构和功能组使其成为药用化学和材料科学研究的宝贵候选物.

结构式图片

上下游产品

9-氯-1-硝基吖啶 1-Nitro-9-Chloroacridine 17431-90-2
1-Nitro-9-Phenoxyacridine 64670-84-4

合成工艺路线路线简述

    📜2-(3-硝基苯胺基)苯甲酸置于三氯氧磷体系中,用 Various Solvent(S) 作为反应溶剂,化学反应 1.08H,反应生成 尼曲吖啶
    参考文献:Acheson,R. Morrin; Constable,Edwin C.; Wright,R. Gordon Mcr.,Journal Of Chemical Research,Miniprint,1983,# 1,P. 101-132
    标题:Acheson,R. Morrin; Constable,Edwin C.; Wright,R. Gordon Mcr.,Journal Of Chemical Research,Miniprint,1983,# 1,P. 101-132

    海关参考信息

    专利信息


    专利号:US-12391691-B2
    优先权日:2018-11-16
    标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
    发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
    权利人:AMGEN INC
    摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

    专利号:US-2025206736-A1
    优先权日:2019-11-14
    标题 :Synthesis of kras g12c inhibitor compound
    发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
    权利人:AMGEN INC
    摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

    专利号:US-2022233673-A1
    优先权日:2019-06-04
    标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
    发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M
    权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND
    摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

    专利号:US-2022118123-A1
    优先权日:2019-02-22
    标 题 :Combination of ar antagonists and targeted thorium conjugates
    发明人:HAMMER STEFANIE; HAGEMANN URS BEAT; HAENDLER BERNARD; LEJEUNE PASCALE; ZITZMANN-KOLBE SABINE; SCHATZ CHRISTOPH; KARLSSON JENNY
    权利人:BAYER AG; BAYER AS
    摘要:The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.

    专利号:US-2023192682-A1
    优先权日:2019-11-14
    标题:Improved synthesis of kras g12c inhibitor compound

    专利号:US-2023192681-A1
    优先权日:2019-11-14
    标 题 :Improved synthesis of kras g12c inhibitor compound

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Niemira M, Dastych J, Mazerska Z. Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia. Biochem Pharmacol. 2013 Jul 15;86(2):231-41. doi: 10.1016/j.bcp.2013.05.008. Epub 2013 May 18. Epub 2007 Jul 24. Erratum in: Cancer Biol Ther. 2008 Mar;7(3):479.
    6: Robertson IG, Bland TJ, Palmer BD. Effect of substituents on the metabolism of nitracrine in rat. Xenobiotica. 1996 May;26(5):559-69. doi: 10.1016/j.bcp.2012.03.013. Epub 2012 Apr 6.

    合成参考文献


    参考文献:10.1007/bf03190006
    摘要:Degterev IA, Nogueira PCL, Marsaioli AJ, Verces AE. Microsomal metabolism of quinifuryl — a nitrofurylethenyl-quinolone antiseptic possessing antitumor activityin vitro. European Journal of Drug Metabolism and Pharmacokinetics. 1999 Mar;24(1):15–22. doi: 10.1007/bf03190006.
    参考文献:10.1016/s1734-1140(11)70499-6
    摘要:Cholewiński G, Dzierzbicka K, Kołodziejczyk AM. Natural and synthetic acridines/acridones as antitumor agents: their biological activities and methods of synthesis. Pharmacol Rep. 2011;63(2):305–36. doi: 10.1016/s1734-1140(11)70499-6.
    参考文献:10.1023/a:1006242321596
    摘要:Adjei AA. Current status of pyrazoloacridine as an anticancer agent. Invest New Drugs. 1999;17(1):43–8. doi: 10.1023/a:1006242321596.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知